Skip to main content

Table 1 Unadjusted and adjusted odd ratios (ORs) for HPV positivity and their corresponding 95% confidence intervals (CIs) according to selected descriptive characteristics among 3008 women in Qatar

From: Molecular epidemiology and genotype distribution of Human Papillomavirus (HPV) among Arab women in the state of Qatar

 

Total no. women

HPV positive, n (%)

Unadjusted OR (95% CI)

Adjusted OR (95% CI)

Age groups

    

16-24

136 (4.5)

7 (5.1)

1

1

25-34

756 (25.1)

44 (5.8)

1.14 (0.50-2.58)

1.20 (0.53-2.73)

35-44

919 (30.6)

51 (5.5)

1.08 (0.48-2.44)

1.15 (0.51-2.59)

45-54

835 (27.8)

54 (6.5)

1.27 (0.57-2.86)

1.36 (0.60-3.07)

≥55

362 (12.0)

26 (7.2)

1.43 (0.60-3.37)

1.49 (0.63-3.54)

Cytology results

    

Normal cytology

2959 (98.4)

173 (5.8)

1

1

Abnormal cytology

49 (1.6)

9 (18.4)

3.62 (1.73-7.59)*

3.68 (1.75-7.75)

Clinical findings

    

Routine smear test

2401 (79.8)

142 (5.9)

1

1

Symptomatic results≠

607 (20.2)

40 (6.6)

1.12 (0.78-1.61)

1.15 (0.80-1.65)

Nationality

    

Qatari

1404 (46.7)

87 (6.2)

1

1

Non-Qatari

1604 (53.3)

95 (5.9)

0.95 (0.71-1.29)

1.00 (0.73-1.36)

Nationality

    

Qatari

1404 (46.7)

87 (6.2)

1

--

Egyptian

465 (15.5)

26 (5.6)

0.90 (0.57-1.41)

 

Arabian peninsula$

310 (10.3)

14 (4.5)

0.72 (0.40-1.28)

 

Fertile Crescent£

566 (18.8)

37 (6.5)

1.06 (0.71-1.58)

 

North Africa#

95 (3.2)

7 (7.4)

1.20 (0.54-2.68)

 

East Africa^

168 (5.6)

11 (6.5)

1.06 (0.55-2.03)

 
  1. *p-value < 0.05.
  2. $Arabian Peninsula excluding Qatar (KSA, Kuwait, Bahrain, UAE, Oman, Yemen).
  3. £Fertile Crescent excluding Egypt (Iraq, Jordan, Lebanon, Palestine, Syria).
  4. #North Africa (Morocco, Algeria, Tunisia, Libya and Mauritania).
  5. ^East Africa (Somalia, Djibouti, Sudan and Comoros).
  6. ≠Symptomatic results include: cervical erosion, genital warts, lower abdominal pain, menorrhagia, pelvic pain, post coital bleeding, primary infertility, secondary infertility, vaginal bleeding, vaginal discharge, vaginal spotting and vulva itching.